Edward P Cohen completed his medical studies at Washington University (St Louis). Postdoctoral studies were at the University of Chicago, the NIH and the
University of Colorado. He has been a member of the faculty of Rutgers University, the University of Chicago and, most recently, the University
of Illinois. Cohen has published more than 135 peer-reviewed papers, in the field of tumor immunology, numerous reviews and book chapters.
Currently, Cohen is the CEO of Immune Cell Therapy, Inc., a tumor vaccine company
Edward P Cohen(Research Area)
Edward P Cohen research interest is on Cellular Immunology, Immunity, cancer, cancer antigens.
Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Rehovot Israel and postdoctoral NIH, USA and UCLA School of Medicine. She is the director of Molecular Microbiology laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Beer Sheva, Israel. He has published more than 65 papers in reputed journals.
Yaffa Mizrachi Nebenzahl(Research Area)
Yaffa Mizrachi Nebenzahl research expertise is on Biochemical and molecular viral and bacterial biology, Cell biology, Viral and bacterial pathogenesis, Innate and adaptive immune response to pathogens
Dr Kushnir is an Integrative Immunologist and distinguished scientist. She is an international speaker and educator, leading clinical innovator who joins molecular biology knowledge with ancient Chinese medicine methods. Dr Kushnir published her work on neuroimmune mediators in the top scientific journals.
Nataliya M Kushnir(Research Area)
Dr Kushnir's research interest is based on Allergy, Immunology
Dr. Wassil Nowicky Dipl. Ing., Dr. techn., DDDr. h. c., Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) at the end of 1955 with graduation to Diplom Ingenieur in 1960 which title was nostrificated in Austria in 1975. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor honoris causa of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of the National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
Wassil Nowicky(Research Area)
Dr. Wassil Nowicky research interest is on Immunology, cancer, cancer antigens, immunity
Harry W Schroeder Jr completed his MD PhD at the age of 28 years from Baylor College of Medicine. He then completed residency in Internal Medicine at the age of 31 at the University of Kentucky, fellowship in Medical Genetics at the University of Washington, postdoctoral studies at the Howard Hughes Medical Institute at the University of Washington, and a sabbatical year at the Institute for Genetics at the University of Cologne. He is the director of the Program in Immunology at the University of Alabama at Birmingham,. He has published more than 120 papers in reputed journals and has served as an editorial board member several journals of repute.
Harry W. Schroeder(Research Area)
Harry W. Schroeder research expertise is on B cell and repertoire development and Genetics of primary immune deficiency diseases.
Dr. Julia Y. Ljubimova, M.D., Ph.D. has been President and Chief Scientific Officer of Arrogene, Inc. since January 11, 2012. Dr. Ljubimova serves as Director of Molecular Oncology for the Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery at Cedars-Sinai Medical Center. Dr. Ljubimova founded Arrogene, Inc. in 2007. Dr. Ljubimova serves as a Director of Nanomedicine Center and Professor of Neurosurgery at Cedars-Sinai Medical Center. Her primary research interests involve methods to block human glioma growth, brain and breast tumor treatments and the effects of air pollution on the brain. She has been a Director of Arrogene, Inc. since January 11, 2012. Dr. Ljubimova is working at Cedars-Sinai since 1993. Dr. Ljubimova's studies have been published in numerous peer-reviewed publications, including Cancer Research, Cancer, American Journal of Pathology and International Journal of Oncology. She is serving on the National Institute of Health Study Section Ã¢â‚¬Å“Nanoscience for Biology and MedicineÃ¢â‚¬Â. Dr. LjubimovaÃ¢â‚¬â„¢s research is funded by the grants from the National Institutes of Health and other government organizations.
Julia Ljubimova(Research Area)
Julia Ljubimova, MD, PhD, is director of the Nanomedicine Research Center in the Cedars-Sinai Department of Neurosurgery. Her main interests are differential cancer gene expression as a tool for finding novel and early markers of cancer growth and development, and the design of new nanomedicine drugs against tumor targets. The Nanomedicine Research Center has developed several nanobioconjugates that selectively target brain and breast cancer and thus could have less dose-limiting toxicity than existing therapies. Ljubimova joined the faculty at Cedars-Sinai to direct studies combining basic cancer and translational research for discovering specific tumor markers. One of the novel markers, the structural tumor vessel wall protein laminin-411, is in a clinical trial as a prognostic and diagnostic marker for human glial tumor progression. This discovery led to the development of new technologies for drug delivery and engineering of the new class of imaging and anti-cancer nanomedicines for MRI cancer-specific diagnostics and inhibition of tumor-specific molecular targets. Ljubimova also is studying the influence of air pollution on activation of molecular markers in the brain that can lead to differential expression of genes that play an important role in tumorigenesis. Her studies have been published in peer-reviewed journals including Cancer Research, Cell, The American Journal of Pathology, Angiogenesis, Nanomedicine and Proceedings of the National Academy of Sciences. Her research is funded by grants from the National Institutes of Health along with state and private funds. Current investigations include the drug delivery system passing through the blood-brain barrier to deliver drugs to brain tumors and having the ability to block several cancer-specific tumor markers by using biodegradable nanoconjugate for brain and breast tumors; cancer-specific drug targeting; and development of nano-imaging agents for the brain tumor "virtual biopsy" using MRI.
Eggehard Holler, PhD, is Professor of Neurosurgery and Biomedical Sciences, and Director of Syntheses at Nanomedicine Research Centre, Department of Neurosurgery, Cedars-Sinai Medical Centre, Los Angeles, USA. He has completed his PhD at the age of 26 years from University of Regensburg, DE, postdoctoral appointments at Cornell and Berkeley, Professor of Biochemistry at University of Regensburg until 2005, and since 2008 Research Scientist and Professor at Cedars-Sinai Medical Centre, USA. He has served at several international universities as visiting Professor, published more than 150 papers and was interims director of Institute of Biophysical Chemistry at Regensburg.
Eggehard Holler(Research Area)
The research of Eggehard Holler, PhD, focuses on design, synthesis and characterization of novel nanoscale drug delivery systems based on polymalic acid. These "nano drugs" are single macromolecules, which are applicable in personalized medicine especially cancer treatment. They provide targeting of tumor markers and an array of prodrugs which are activated at the site of targeted cells in resonse of specific cellular stimuli. The nanomedicine was established in preclinical models of solid breast and brain tumors and for brain metastases and is prepared for translation into clinics. After appropriate modifications, the nanomaterial was transformed into reagents for differential diagnosis by MRI of solid and metastatic brain tumors. Research grants: NIH/NCI R01 CA123495; NIH/NCI R01 CA136841; NIH/NCI, U01 CA151815; The Martz Translational Breast Cancer Research Fund. In addition, grants by PB/SCAQMD; BTAP007 AQMD on traffic air pollution, such as heavy metals acquired by breathing and activation of signal pathways that might lead to brain malignancies.
Prof. Chak Thida, completed MD at the age of 27 years from the University of health Sciences (UoHS), Phnom Penh (P-P), Cambodia and postdoctoral studies to be a psychiatrist at the age 0f 40 from the UoHS, Phnom Penh and University Oslo, Norway, Director of psychiatric department of the UoHS, P-P and Vice director of Khmer Soviet Friendship Hospital, P-P. Prof. Chak Thida have been international published 2 papers and have been local study for more than 15 papers serving as an editorial board member of repute.
Chak Thida (Research Area)
Prof. Chak Thida research interest is on Psychological distress, HIV/AIDS and ARV
Professor Andrzej K. Siwicki, VMD, Ph.D., DSc is a head of Department Microbiology and Clinical Immunology, Faculty of Veterinary Medicine, University of Warmia and Mazury and Department of Pathology and Immunology IFI in Olsztyn, Poland. He is author of over 500 original papers in reputed journals and about 200 scientific communications (index-h 32, index of citation: 4502). His fields of interest are modulation of defence mechanisms and protection against diseases by natural and synthetic products in animals, influence of pollutants on the cell-mediated immunity and restoration of immunity after suppression induced by xenobiotics. Developed a new possibility in the comparative immunotoxicology for control of effect of xenobiotics and pharmaceutical products on the defence mechanisms and protection against diseases. He attended scientific missions in USA, Japan, France and Israel, was a co-ordinator of USDA and FAO projects and he is professor conferring of 14 PhDs and 4 DSc.
Andrzej K. Siwicki(Research Area)
Andrzej Siwicki research expertise is on microbiology and clinical immunology and assesses the impact of xenobiotics on the animal and human body. The scope of scientific activity includes: pathogenicity of selected groups of viruses and bacteria, Evaluation of the effects of chemotherapeutics and other xenobiotics on immunocompetent cells and cell and humoral immune responses, immunohomostasis immunoassay, modulation of cell and humoral immunity after xenobiotics-induced suppression, improvement of rapid diagnostic methods for viral and bacterial diseases using monoclonal antibody and cytometry techniques application of molecular biology in the diagnosis of infectious diseases and therapy, improvement of immunoprophylaxis methods: biostimulators, mono and polyvalent and recombinant vaccines and epidemiology associated with zoonoses.
John Yu is Distinguished Chair Professor/Director, Institute of Stem Cell/Translational Cancer Research, CGMH. He is also Distinguished Visiting Research Fellow at Institute of Cellular & Organismic Biology, Academia Sinica, and was the Director for the same Institute (2002-2009). He is the founding President for Taiwan Society for Stem Cell Research. Dr. Yu was elected to serve in many ISSCR Committees USA, the Steering Committee of Asia-Pacific Stem Cell Network, and advisor for Stem Cell Biology, Kumamoto Univ. He was Director of Exp. Hematology (1998-2002) at Scripps Research Institute, USA. He received an Established Investigatorship Award from American Heart Assoc. and many other awards
Reinhard Pabst is the Professor of Institute for Immunomorphology, Centre of Anatomy Medical School Hannover, Germany. 2002 to 2006 he was Dean for Research at Medical School Hannover. He was Head of Institute of Functional and Applied Anatomy 1992 to 2009. From 2009 to 2015 he was Senior Research Prof. in Immunohistology.
Reinhard Pabst(Research Area)
Reinhard Pabst research expertise is on lymphocyte migration, bone marrow, Regeneration of auto transplanted fragments of lymph nodes.
Marcus Saemann is Head of the 6th Medical Department with Nephrology and Dialysis, Wilhelminenspital Vienna, Austria.
Previously, he was senior consultant nephrologist, at the Medical University of Vienna, Austria. He has more than 15 years of experience in all branches of nephrology including the whole spectrum of clinical nephrology, acute kidney injury, chronic kidney diseases, kidney transplantation, kidney-pancreas transplantation, intensive care nephrology, all extracorporal strategies such as hemodialysis, hemofiltration, peritoneal dialysis, along with plasmapheresis including immunoadsorption. Further clinical focus is the treatment of both type 1 and 2 diabetes mellitus especially with chronic kidney disease (diabetic kidney disease).
Marcus Saemann(Research Area)
Marcus Saemann research interest is on Diabetic kidney disease including Renin-Angiotensin-Aldosteron-System, HDL Cholesterol in Chronic Kidney Disease, Post-Transplant Diabetes mellitus,Diabetes management including insulin pump and continuous glucose measurement (CGM) technology (artificial pancreas, Immunosuppression after renal transplantation, especially mTOR inhibition, CMV infection, Urinary tract infection
Dr. Rongtuan Lin is Associate Professor - Department of Medicine, Division of Experimental Medicine. He has published more than 20 papers in differebt journals. he is involved in many projects such as Regulation of the interferon antiviral defense pathway, Small molecule agonists of the RIG-I pathway as innate stimulatory agents against virus infection, Combination oncolytic virotheapy for the treatment of prostate cancer.
Rongtuan Lin(Research Area)
Dr. Rongtuan Lin research interest is on Innate Immunity, Interferon Sginaling, Viral Evasion.
Dr. Kwon had his PhD from the Georgia Regents University, in 1981 and postdoctoral studies at the Department of Human Genetics, Yale University from 1981 to 1984. Dr. Kwon was a tenured Professor of the Indiana University School of Medicine, a Professor and Director of the Immunomodulation Research Center at the University of Ulsan, a Distinguished Professor and Investigator at the National Cancer Center, Korea, and Professor at the Department of Medicine Tulane University, New Orleans LA . He is currently the Founder and CEO of Eutilex who is developing T cell therapeutics and immunomodulatory antibody therapeutics. He has published over 300 peer-reviewed papers and has been serving as an editorial member of reputable journals.
Byoung S. Kwon(Research Area)
Byoung S. Kwon research expertise is focuses on immunotherapy against cancers and autoimmune diseases. Dr. Kwon has established a concept called â€œinducible costimulationâ€ by discovering 4-1BB-4-1BBL and AITR-AITRL systems. He has proved that immune functions can be selectively suppressed or enhanced through the inducible costimulation and presented the possibility of â€œselective immunotherapyâ€. Antigen-specific T cell therapeutics that Dr. Kwonâ€™s team has developed are in phase 1 trials against various cancers in the NCC.